Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ADNEURIS THERAPEUTICS, INC. via MAD GLOBAL STRATEGY
2026 · third_quarter · Q3
Education on new drug seeking FDA approval
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALUCHEM INC. via MAD GLOBAL STRATEGY
2026 · third_quarter · Q3
Source: Senate LDA
foreign investment
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), Vice President of the U.S.
EMPOWER EIT via MAD GLOBAL STRATEGY
2026 · third_quarter · RR
Issues related to support lithium development and commercialization. Issues related to lithium technology.
Issues related to support lithium development and commercialization. Issues related to lithium technology.
Issues related to support lithium development and commercialization. Issues related to lithium technology.
ALUCHEM INC. via MAD GLOBAL STRATEGY
2026 · second_quarter · Q2
foreign investment
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), Vice President of the U.S.
ADNEURIS THERAPEUTICS, INC. via MAD GLOBAL STRATEGY
2026 · second_quarter · Q2
Education on new drug seeking FDA approval
Filing targets: SENATE
ADNEURIS THERAPEUTICS, INC. via MAD GLOBAL STRATEGY
2026 · second_quarter · RR
FDA approval of new drug
FDA approval of new drug
ALUCHEM INC. via MAD GLOBAL STRATEGY
2026 · first_quarter · RR
Foreign investment